Continuing its search for promising external compounds, Ipsen SA has signed an exclusive global pact with BAKX Therapeutics to research, develop, manufacture and commercialize the US biotech’s investigational therapy BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors, by targeting the B-cell lymphoma-2 (BCL-2) family of proteins.
The alliance reflects Ipsen’s continued aim to strengthen its pipeline, specifically in the oncology and neurology spaces. It comes shortly...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)